SCHEDULE 13D/A: 23andMe CEO Anne Wojcicki Sweetens Buyout Offer with New Financing and Cost Cuts, Aims to Avert Bankruptcy

Anne Wojcicki, CEO of 23andMe Holding Co., has submitted an updated proposal to acquire all outstanding shares not owned by her and affiliates, maintaining the total consideration of up to $2.94 per share while offering new financing and committing to significant operating expense reductions to avoid bankruptcy.

Summary

• Anne Wojcicki has submitted an updated proposal (the 'March 10 Proposal') to acquire all outstanding shares of 23andMe Holding Co. not owned by her and her affiliates, or other invited rollover stockholders.
• The total consideration remains up to $2.94 per share, consisting of $0.41 per share in upfront cash and three contingent value rights (CVRs) totaling $2.53 per share.
• The CVRs are payable upon achieving specific annual revenue milestones: $0.68/share if FY26 revenue exceeds $224 million, $0.84/share if FY27 revenue exceeds $295 million, and $1.01/share if FY28 revenue exceeds $367 million.
• The CVRs would be structured as non-tradable contracts.
• Ms. Wojcicki is willing to provide $30 million of unsecured financing to the Company at a 7% interest rate, with maturity after the closing of the potential transaction, requiring no immediate payments.
• An additional $20 million commitment to fund operations will be provided, offset dollar-for-dollar by any future financing Ms. Wojcicki is able to raise.
• Ms. Wojcicki is committed to enacting $15 million of annual operating expense reductions to focus on the core business.
• The proposal is conditioned on approval by the Special Committee of the Board of Directors (with independent advisors) and a non-waivable condition requiring approval by a majority of shares not owned by Ms. Wojcicki, her affiliates, or rollover stockholders.
• The proposal is presented as a means to return immediate value to stockholders and avoid bankruptcy for the Company.
• Sources of funds for the transaction total $137 million, including $2 million from Anne Wojcicki Rollover Equity, $10 million in New Capital, $75 million from Cash from Operations, $30 million from a Bridge Loan, and $20 million from Additional Equity Commitments.
• Uses of funds total $137 million, allocated as $87 million for Equity Purchase Price and $50 million for Funding for Operations.
• Ms. Wojcicki, through various entities, beneficially owns 5,659,700 shares of Class A Common Stock, representing 21.9% of the outstanding Class A Common Stock.

Sentiment

Score: 7

Explanation: The proposal offers a clear path to avoid bankruptcy, provides immediate cash to shareholders, and includes significant financing commitments. While CVRs introduce uncertainty and are non-tradable, the overall sentiment is positive given the stated alternative of bankruptcy and the protections for minority shareholders.

Positives

• The proposal offers immediate cash consideration of $0.41 per share to shareholders.
• Potential for significant additional value of up to $2.53 per share through CVRs, contingent on future revenue growth.
• Ms. Wojcicki is providing $30 million in unsecured financing at a 7% interest rate, with no immediate payments required, to support company operations.
• An additional $20 million commitment to fund operations demonstrates confidence and provides further financial support.
• A commitment to $15 million in annual operating expense reductions aims to improve financial efficiency and focus on the core business.
• The proposal explicitly states its intent to avoid bankruptcy for the Company, addressing a critical financial concern.
• The inclusion of a non-waivable condition requiring approval from a majority of non-Wojcicki shares provides a safeguard for minority shareholders.

Negatives

• The majority of the proposed consideration ($2.53 out of $2.94 per share) is tied to contingent value rights (CVRs) which are not guaranteed and depend on future revenue milestones.
• The CVRs are non-tradable, meaning shareholders cannot sell their rights to future payments, limiting liquidity.
• The proposal is non-binding and can be modified or withdrawn at any time, creating uncertainty.
• The underlying context of the proposal is to 'avoid bankruptcy for the Company,' indicating significant financial distress.
• The 'up to' $2.94 per share total consideration implies the full amount is not guaranteed.

Risks

• There is no assurance that the March 10 Proposal will result in any definitive agreement, transaction, or any other strategic alternative.
• The Reporting Persons (Anne Wojcicki and affiliates) reserve the right to modify or withdraw the March 10 Proposal at any time without prior notice.
• The achievement of CVR milestones is uncertain and depends on the Company's ability to meet specific revenue targets in fiscal years 2026, 2027, and 2028.
• The Company faces the risk of bankruptcy if the potential transaction does not materialize or if its operations are not adequately funded.

Future Outlook

The proposal aims to provide immediate value to stockholders and prevent the Company's bankruptcy by injecting capital and implementing cost reductions. Future value for shareholders is contingent on the Company achieving specific revenue milestones in fiscal years 2026, 2027, and 2028, which would trigger CVR payments. The focus on core business through expense reductions is intended to increase the likelihood of returning future value.

Management Comments

• "I am submitting this updated proposal for the acquisition of all of the outstanding shares of capital stock of 23andMe, not owned by me and my affiliates (or any other stockholders I invite to roll over their current equity ownership)."
• "The total consideration I am willing to pay has not changed from my March 6 Offer: total consideration of up to $2.94 per share, including upfront cash consideration of $0.41 per share and three contingent value rights (CVRs) representing the potential to receive an additional $2.53 per share in the aggregate, upon the achievement of the milestones described below."
• "As part of my Proposal, as requested by the Special Committee, I am willing to provide $30 million of unsecured financing to the Company to finance its operations and that of its subsidiaries through the closing of the Potential Transaction, at a 7% interest rate and a maturity date after the closing of the Potential Transaction. This loan will not require immediate payments by the Company."
• "In addition to the $30 million loan, to demonstrate my confidence in the future of the Company, I am also willing to provide an additional $20 million commitment to fund the operations of the Company, which commitment will be offset dollar-for-dollar by any future financing I am able to raise."
• "I am also committed to enacting $15 million of annual operating expense reductions to focus on the core business and increase the likelihood of returning future value to shareholders."
• "I will only engage in a Potential Transaction or any other corporate acts related to a Potential Transaction if the Special Committee is empowered to consider (including the ability to reject) any such proposal by me with the assistance of its own legal and financial advisors, and the Special Committee approves such proposal."
• "Furthermore, I will only engage in a Potential Transaction (and any other corporate acts related to a Potential Transaction) if, in addition to any other vote required, such transaction is subject to a non-waivable condition requiring approval of a majority of the shares of common stock of the Company not owned by me, any other stockholders who are invited to roll over their shares, or any of their respective affiliates, and such approval is in fact obtained prior to the consummation of such transaction."
• "I believe this is a transaction that answers the Special Committees requests, returns immediate value to our stockholders and avoids bankruptcy for the Company."

Industry Context

This announcement reflects a significant internal corporate action for 23andMe, driven by its CEO and a major shareholder, Anne Wojcicki, to take the company private. The explicit mention of 'avoiding bankruptcy' suggests the company is facing severe financial challenges, which could be indicative of broader pressures within the direct-to-consumer genomics or broader biotechnology sectors, or specific operational difficulties unique to 23andMe.

Corporate Governance

Related Party Transactions

• The entire proposal is a related party transaction, as it is an offer from Anne Wojcicki, the CEO and a significant beneficial owner (21.9% of Class A Common Stock), to acquire the remaining outstanding shares of 23andMe Holding Co. not owned by her and her affiliates.
• The proposed $30 million unsecured financing and $20 million additional commitment are also related party transactions from Ms. Wojcicki to the Company.

Stakeholder Impact

• **Shareholders:** Potential for immediate cash and future contingent value through CVRs, with a non-waivable majority-of-the-minority vote providing protection. The proposal aims to avoid bankruptcy, which would be detrimental to shareholders.
• **Employees:** The proposal includes a commitment to $15 million in annual operating expense reductions, which could potentially lead to workforce adjustments, but also aims to stabilize the company and avoid bankruptcy, which would preserve jobs.
• **Company (23andMe Holding Co.):** Receives critical unsecured financing ($30 million loan) and an additional $20 million commitment to fund operations, which is stated as necessary to avoid bankruptcy. The proposal also commits to focusing on the core business through expense reductions.
• **Creditors:** The provision of new financing and the stated goal of avoiding bankruptcy would likely be positive for creditors, reducing the risk of default.

Next Steps

• The Reporting Persons intend to engage in discussions with the Special Committee regarding the terms of the March 10 Proposal.
• The Reporting Persons may change the terms of the March 10 Proposal, determine to accelerate or terminate discussions, or withdraw the proposal at any time.
• The Reporting Persons reserve the right to formulate other plans or make other proposals.
• The Reporting Persons and their affiliates will continue to take steps to further the proposal or support their investment, including discussions with advisors and entering into agreements.
• The potential transaction is subject to approval by the Special Committee and a majority of the shares of common stock not owned by Ms. Wojcicki or her affiliates/rollover stockholders.

Key Dates

Recommendation

Keywords

23andMe, Anne Wojcicki, acquisition proposal, Schedule 13D/A, contingent value rights, CVRs, going private, financing, biotechnology, genomics, direct-to-consumer genetics, corporate governance, special committee, shareholder approval, bankruptcy avoidance